LL-37 Tracker App
Log Doses, Monitor Infection Markers, and Track Immune Support Response
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid innate immune defence molecule naturally secreted by neutrophils, epithelial cells, and NK cells in response to infection and injury. It exhibits direct antimicrobial activity against bacteria, viruses, and fungi, disrupts pathogenic biofilms, modulates innate immune signalling, and promotes wound healing. Shotlee tracks every LL-37 dose, infection marker, immune lab value, and healing metric in one free app.
What Is LL-37?
LL-37 is the sole human cathelicidin, produced from the hCAP18 precursor protein via neutrophil elastase cleavage. Named for its 37-amino-acid length beginning with two leucines (LL), it is a key component of innate immune defence — deployed at skin barriers, mucosal surfaces, and wound sites. LL-37 levels are naturally upregulated by vitamin D3 and by acute infection signals.
Beyond direct antimicrobial activity, LL-37 modulates immune signalling: it acts as a chemoattractant for monocytes and neutrophils, promotes dendritic cell maturation, and stimulates angiogenesis and keratinocyte migration for wound closure. Its anti-biofilm activity is of particular interest in the context of chronic infections involving antibiotic-resistant biofilm-forming bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus.
Protocol Options
Lower-end dose used for general immune modulation and antimicrobial support. Often used as a starting dose to assess individual tolerance.
Higher research dose for chronic infection support, anti-biofilm applications, or wound healing acceleration. Typical cycle: 4–8 weeks.
Mechanism of Action
Research Highlights
What to Track in Shotlee
Build a complete antimicrobial and immune support diary — doses, infection markers, wound progress, and immune labs.
LL-37 for Chronic Infections and Anti-Biofilm Applications
Chronic infections — particularly those involving biofilm-forming organisms — represent a significant gap in conventional antibiotic therapy. Biofilms protect bacteria from both immune clearance and antibiotic penetration by orders of magnitude. LL-37 disrupts biofilm matrix integrity through a different mechanism than conventional antibiotics, making the combination potentially synergistic.
Some researchers exploring LL-37 for chronic sinus infections, recurrent UTIs, or wound infections log simultaneous conventional antibiotic use alongside LL-37 doses in their Shotlee tracker. This allows retrospective analysis of whether combination protocols correspond to faster symptom resolution compared to antibiotic-only cycles.
Protocol FAQs
LL-37 is the only human cathelicidin antimicrobial peptide. In preclinical research it is studied for broad-spectrum antimicrobial activity, anti-biofilm effects (particularly against antibiotic-resistant bacteria), immune modulation, and wound healing acceleration. It is not approved for human use.
Research protocols typically use 100–300 mcg subcutaneously once daily, with cycles of 4–8 weeks. Lower doses (100 mcg) are often used as starting points to assess individual tolerance before escalating.
LL-37 disrupts bacterial cell membranes physically, rather than targeting specific enzymatic processes. This broad membrane disruption mechanism reduces the likelihood of resistance development. It also targets biofilms, which conventional antibiotics typically cannot penetrate effectively. LL-37 additionally has immune-modulatory effects that antibiotics lack.
Key markers include WBC and differential (immune activity), CRP (systemic inflammation), and procalcitonin (bacterial infection severity). For wound applications, wound measurement and photography provide the most direct evidence of response. Log all results with dates in Shotlee.
LL-37 and Thymosin Alpha-1 are frequently considered together — LL-37 provides direct antimicrobial and anti-biofilm defence while Thymosin Alpha-1 strengthens adaptive immune responses (T cell maturation, NK cell activity). Log each compound separately in Shotlee to track individual contributions.
Track Your LL-37 Protocol in Shotlee
Log doses, monitor WBC and CRP, document wound healing photos, and track your immune support response — all free in Shotlee.